Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Insight Molecular Diagnostics (IMDX) Research & Development (2020 - 2025)

Insight Molecular Diagnostics (IMDX) has disclosed Research & Development for 6 consecutive years, with $5.8 million as the latest value for Q4 2025.

  • Quarterly Research & Development rose 158.26% to $5.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $15.9 million through Dec 2025, up 61.72% year-over-year, with the annual reading at $15.9 million for FY2025, 61.6% up from the prior year.
  • Research & Development hit $5.8 million in Q4 2025 for Insight Molecular Diagnostics, up from $3.9 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $5.8 million in Q4 2025 to a low of $1.4 million in Q4 2022.
  • Historically, Research & Development has averaged $2.8 million across 5 years, with a median of $2.5 million in 2021.
  • Biggest five-year swings in Research & Development: tumbled 69.98% in 2022 and later soared 158.26% in 2025.
  • Year by year, Research & Development stood at $4.6 million in 2021, then crashed by 69.98% to $1.4 million in 2022, then skyrocketed by 84.83% to $2.5 million in 2023, then decreased by 11.39% to $2.3 million in 2024, then soared by 158.26% to $5.8 million in 2025.
  • Business Quant data shows Research & Development for IMDX at $5.8 million in Q4 2025, $3.9 million in Q3 2025, and $3.3 million in Q2 2025.